- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Value Discussion Reemerges at NICE: Roche's Gazyvaro Rejected
Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.
Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.
In August the National Institute for Health and Care Excellence (NICE) rejected the Swiss drugmaker's drug Kadcyla for an aggressive form of breast cancer. Roche had proposed a discount for that drug, which carries a full list price of more than 90,000 pounds for a course of treatment.
Friday's decision promises to further sour relations between NICE and the world's biggest maker of cancer drugs, which two months ago said NICE was "not fit for purpose".
Read the report on Reuters: http://reut.rs/1CIwReZ
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
